SCHEMBL2692835

SCHEMBL2692835

CC(C)(C)OC(=O)NC1CC(OC(=O)c2ccccc2)CN(C(=O)O)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KDM1A O60341 1/20 0.44
MAOB P27338 1/20 0.44
CHRNA7 P36544 2/20 0.43
HSD11B1 P28845 2/20 0.43
CYP2C9 P11712 1/20 0.43
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR3A P46098 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
USP30 Q70CQ3 2/20 0.42
EPHX2 P34913 1/20 0.41
MEN1 O00255 1/20 0.41
NAMPT P43490 1/20 0.40
KCNA3 P22001 1/20 0.39
APOBEC3A P31941 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
CKS1B P61024 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4120545 0.86 PDE4B (0.48) KMT2AL3MBTL1KDM1AMAOBHSD11B1
SCHEMBL29942104 0.86 KMT2A (0.52) KMT2AL3MBTL1KDM1AMAOBCHRNA7
SCHEMBL15046770 0.86 KMT2A (0.52) KMT2AL3MBTL1KDM1AMAOBCHRNA7
SCHEMBL3410876 0.80 EPHX2 (0.48) KMT2AL3MBTL1KDM1AMAOBCHRNA7
SCHEMBL21178208 0.80 BTK (0.46) KMT2AL3MBTL1KDM1AMAOBHSD11B1
SCHEMBL1710227 0.80 BTK (0.46) KMT2AL3MBTL1KDM1AMAOBHSD11B1
SCHEMBL1710470 0.79 BTK (0.53) KMT2AL3MBTL1KDM1AMAOBHSD11B1
SCHEMBL8298895 0.77 NAMPT (0.54) KMT2AL3MBTL1KDM1AMAOBCHRNA7
SCHEMBL2694052 0.77 PIM1 (0.42) KMT2AL3MBTL1KDM1AMAOBCHRNA7
SCHEMBL2694057 0.77 PIM1 (0.42) KMT2AL3MBTL1KDM1AMAOBCHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829193-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-09 US disclosed
EP-2262802-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-10-23 EP disclosed
EP-2596790-A1 Pim kinase inhibitors and methods of their use Novartis AG (CH) 2013-05-29 EP disclosed
US-20120202851-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-08-09 US disclosed
US-8168794-B2 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-01 US disclosed
EP-2262802-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2010-12-22 EP disclosed
US-20100216839-A1 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-26 US disclosed
WO-2009109576-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216839-A1 Pim kinase inhibitors and methods of their use PIM1, PIM2, PIM3 KMT2A 1446/4885L3MBTL1 1858/4885KDM1A 1654/4885
US-20120202851-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 KMT2A 1446/4885L3MBTL1 1858/4885KDM1A 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.